Bartosz Hudzik: Better Control, Similar Tolerability With Quadruple Therapy in Resistant Hypertension
Bartosz Hudzik, Editorial Consultant at JACC Case Reports, shared a post on LinkedIn about a recent article by Stefano Taddei et al, published in European Society of Cardiology:
”Resistant hypertension is often treated as a dosing problem.
But what if it’s actually a strategy problem?
Patients with true resistant hypertension face markedly higher risks of stroke, heart failure, kidney disease, and death — yet many remain on prolonged triple therapy despite uncontrolled BP.
The Phase 3 QUADRO trial challenges that inertia.
Switching patients from standard triple therapy to the first full-dose quadruple single-pill combination (adding bisoprolol) delivered:
- −8 mmHg additional systolic BP reduction in just 8 weeks
- Confirmed improvement on 24-hour ambulatory monitoring
- No serious safety concerns
- A single pill instead of therapeutic escalation by fragmentation
In other words: better control, similar tolerability, potentially better adherence.
If resistant hypertension drives disproportionate cardiovascular risk, should we be escalating faster — and simplifying sooner?”
Title: Quadruple vs triple therapy for resistant hypertension: the QUADRO trial
Authors: Stefano Taddei, Krzysztof Narkiewicz, Stéphanie Bricout-Hennel, Parvoleta Petrova, Cécile Batailler, Roland Asmar
Read the Full Article on European Society of Cardiology․
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 31, 2026, 16:05Happy National Doctors’ Day to All Physicians Making a Difference – ASH
-
Mar 31, 2026, 16:03Robert Negrin: Strengthening Collaboration with NCI to Advance Hematology Research
-
Mar 31, 2026, 16:02Jim Hoffman: Does Multiomics Suggest LC PASC Patients Require Multiple Drugs to Correct Biochemical Dysregulation?
-
Mar 31, 2026, 15:59Seema Dawood: Blister Cell in G6PD Deficiency
-
Mar 31, 2026, 15:57Ney Carter Borges: Clopidogrel vs Aspirin in Long-Term Monotherapy
-
Mar 31, 2026, 15:57Join the Webinar on Immunoglobulin Access and Stewardship in the UK and Australia – ISBT
-
Mar 31, 2026, 15:55Hind El Azzazi: Successful Defense of My Medical Doctorate on Antiphospholipid Syndrome in Men
-
Mar 31, 2026, 15:54Rucha Patil: Honored to Speak at AIIMS Nagpur ToT Workshop on Non-Factor Therapy in Hemophilia A
-
Mar 31, 2026, 15:43Deepak Sudheendra: When the Clot Is Gone, but Symptoms Remain